Sale!

CCDC114 Gene Primary Ciliary Dyskinesia Type 20 Genetic Test

Original price was: $700.Current price is: $500.

-29%

The CCDC114 Gene Primary Ciliary Dyskinesia Type 20 NGS Genetic DNA Test is a comprehensive diagnostic tool that identifies mutations in the CCDC114 gene responsible for Primary Ciliary Dyskinesia (PCD) Type 20. This advanced next-generation sequencing test analyzes the complete coding region of the CCDC114 gene to detect pathogenic variants that disrupt ciliary function, leading to chronic respiratory infections, sinusitis, and fertility issues. The test is particularly valuable for individuals with recurrent respiratory infections, chronic sinusitis, bronchiectasis, or situs inversus. Early diagnosis through this $500 USD test enables proactive management strategies, personalized treatment plans, and informed family planning decisions. Our genetic testing services are available nationwide with convenient sample collection options including blood, extracted DNA, or simple blood spot cards.

Trusted Testing. Expert Care. Guaranteed Privacy.

  • Accredited and Trusted
  • Expert Scientists, Advanced Technology
  • Data Privacy Guaranteed
Guaranteed Safe Checkout

CCDC114 Gene Primary Ciliary Dyskinesia Type 20 NGS Genetic DNA Test

Comprehensive Genetic Analysis for Primary Ciliary Dyskinesia

The CCDC114 Gene Primary Ciliary Dyskinesia Type 20 NGS Genetic DNA Test represents a cutting-edge diagnostic approach for identifying genetic mutations associated with Primary Ciliary Dyskinesia (PCD), a rare inherited disorder affecting ciliary function throughout the body. This comprehensive genetic analysis utilizes next-generation sequencing technology to provide accurate, reliable results for patients and healthcare providers seeking definitive diagnosis of PCD Type 20.

What Does This Test Measure?

This advanced genetic test specifically targets the CCDC114 gene, which plays a crucial role in the proper formation and function of motile cilia. The test detects:

  • Pathogenic variants and mutations in the CCDC114 gene coding regions
  • Single nucleotide polymorphisms (SNPs) affecting ciliary protein structure
  • Insertions, deletions, and copy number variations impacting gene function
  • Genetic markers associated with impaired mucociliary clearance

Who Should Consider This Test?

This genetic test is recommended for individuals presenting with symptoms suggestive of Primary Ciliary Dyskinesia, including:

  • Chronic respiratory infections beginning in infancy or early childhood
  • Persistent sinusitis and nasal congestion unresponsive to conventional treatments
  • Recurrent middle ear infections and hearing difficulties
  • Chronic cough with excessive mucus production
  • Bronchiectasis or abnormal lung development
  • Situs inversus (organs positioned on opposite sides of the body)
  • Male infertility due to impaired sperm motility
  • Family history of Primary Ciliary Dyskinesia or related respiratory conditions

Clinical Benefits of Genetic Testing

Early and accurate diagnosis through CCDC114 gene testing provides numerous clinical advantages:

  • Definitive Diagnosis: Confirms or rules out PCD Type 20 with high accuracy
  • Personalized Treatment: Enables targeted management strategies for respiratory symptoms
  • Family Planning: Provides crucial information for genetic counseling and reproductive decisions
  • Proactive Management: Facilitates early intervention to prevent complications
  • Comprehensive Care: Supports multidisciplinary approach involving ENT specialists, pulmonologists, and genetic counselors

Understanding Your Test Results

Your genetic test results will be carefully interpreted by our team of certified genetic specialists:

  • Positive Result: Indicates the presence of pathogenic CCDC114 gene mutations confirming PCD Type 20 diagnosis
  • Negative Result: Suggests absence of detectable mutations in the CCDC114 gene, though other genetic causes may need consideration
  • Variant of Uncertain Significance: Identifies genetic changes with unclear clinical impact requiring further evaluation
  • Carrier Status: Determines if you carry one copy of a mutated gene without showing symptoms

Test Details and Pricing

Test Component Details
Test Name CCDC114 Gene Primary Ciliary Dyskinesia Type 20 NGS Genetic DNA Test
Regular Price $700 USD
Discount Price $500 USD
Turnaround Time 3 to 4 Weeks
Sample Type Blood, Extracted DNA, or One Drop Blood on FTA Card
Testing Method Next-Generation Sequencing (NGS) Technology
Specialty ENT Doctor, Genetics Department

Pre-Test Requirements

Before undergoing testing, we recommend:

  • Comprehensive clinical history documentation
  • Genetic counseling session to discuss implications and create family pedigree
  • Review of symptoms and family history with healthcare provider
  • Understanding of potential outcomes and their impact on treatment decisions

Nationwide Testing Availability

We proudly offer our comprehensive genetic testing services across the United States with convenient locations in major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified collection centers ensures accessible testing for patients nationwide.

Take Control of Your Health Today

Don’t let uncertainty about your respiratory health continue. The CCDC114 Gene Primary Ciliary Dyskinesia Type 20 NGS Genetic DNA Test provides the clarity needed for proper diagnosis and management. Our experienced genetic counselors and medical professionals are ready to guide you through the testing process and help interpret your results.

Ready to schedule your test? Call or WhatsApp us today at +1(267) 388-9828 to book your appointment or speak with our genetic specialists. Take the first step toward definitive diagnosis and personalized care.